1. Introduction
===============

Gene regulation via DNA and protein modifications has been intensively studied. However, the knowledge on RNA modifications remains insufficient ([@b1-ijmm-43-06-2267]). Among all mRNA modifications, N^6^-methyladenosine (m^6^A) modification is the most common type in eukaryotic RNA and occurs in three to five sites per transcript on average ([@b2-ijmm-43-06-2267]-[@b4-ijmm-43-06-2267]).

m^6^A was discovered in the 1970s in a wide range of cellular mRNAs ([@b4-ijmm-43-06-2267]-[@b6-ijmm-43-06-2267]). Methylation occurs at the sixth position of nitrogen atoms of adenosine at the post-transcriptional level with S-adenosylmethionine serving as the methyl donor for m^6^A formation, which is termed m^6^A modification ([@b7-ijmm-43-06-2267]-[@b9-ijmm-43-06-2267]).

The reversible activity of the m^6^A modification is regulated by the combined action of methylase and demethylase ([@b10-ijmm-43-06-2267]). The m^6^A methylase complex consists of at least five \'writer\' proteins ([@b11-ijmm-43-06-2267]-[@b14-ijmm-43-06-2267]), among which methyltransferase like 3 (METTL3) protein serves a central role. METTL14 protein supports METTL3 protein structurally ([@b15-ijmm-43-06-2267]), WT1-associated protein (WTAP) regulates the recruitment of the m^6^A methyltransferase complex to mRNA targets ([@b12-ijmm-43-06-2267]) and the RNA-binding motif protein 15 serves a role in helping this complex move towards the appropriate m^6^A sites ([@b16-ijmm-43-06-2267]). Vir like m^6^A methyltransferase associated (VIRMA) is also a component of this m^6^A methylase complex; however, its molecular function remains largely unknown ([@b13-ijmm-43-06-2267]). METTL16 is a newly discovered m^6^A methyltransferase that primarily methylates m^6^A sites in the 3′-untranslated region (3′-UTR) of RNA. When METTL16 is knocked down, the level of m^6^A in the cell decreases by \~20% ([@b17-ijmm-43-06-2267]). Two reported demethylases that reverse m^6^A modification are FTO ([@b18-ijmm-43-06-2267]) and alkB homolog 5 (ALKBH5) ([@b19-ijmm-43-06-2267]). It has been confirmed that m^6^A levels increased following the knockdown of FTO and ALKBH5 expression ([@b18-ijmm-43-06-2267],[@b19-ijmm-43-06-2267]). The identified \'readers\' of m^6^A are YT521-B homology (YTH) domain-containing proteins, including YTHDF1-3, YTHDC1 and YTHDC2, which participate in the translation ([@b20-ijmm-43-06-2267]), stabilization ([@b21-ijmm-43-06-2267]), splicing ([@b22-ijmm-43-06-2267]) or nuclear export ([@b23-ijmm-43-06-2267]) of mRNA. The affinity of \'readers\' has been reported to be higher compared with unmethylated mRNA for m^6^A-methylated mRNA ([@b24-ijmm-43-06-2267]).

m^6^A bases cannot be detected directly by sequencing because the m^6^A modification does not change the base pairing properties and cannot be distinguished from regular bases by reverse transcription ([@b25-ijmm-43-06-2267],[@b26-ijmm-43-06-2267]). Previously, new methods have been developed to identify m^6^A modification in cells, which are based on immunoprecipitation or selective RNA chemistry to isolate modified RNA fragments and combined with high-throughput sequencing ([@b3-ijmm-43-06-2267],[@b25-ijmm-43-06-2267],[@b27-ijmm-43-06-2267]). Dot blot technology is frequently used to observe changes in m^6^A. However, dot blots cannot determine the quantitation and precise location of m^6^A ([@b28-ijmm-43-06-2267]). RNA photo-crosslinkers, quantitative proteomics and electrochemical immunosensor methods may be applied to detect the presence of m^6^A in cells; however, they cannot precisely determine the m^6^A modification sites ([@b29-ijmm-43-06-2267],[@b30-ijmm-43-06-2267]). The newly developed methylated RNA immunoprecipitation sequencing (MeRIP-seq) method combines m^6^A antibody immunoprecipitation and deep sequencing to identify the m^6^A residues in 100-200 nucleotide RNA segments ([@b3-ijmm-43-06-2267],[@b25-ijmm-43-06-2267]). However, this approach is complicated as m^6^A often appears in clusters since multiple different m^6^A-containing fragments generate overlapping reads, which can result in large peaks spanning several m^6^A residues ([@b2-ijmm-43-06-2267]). Thus, the summit of these peaks may not accurately reflect the positions of m^6^A residues. By contrast, when using the m^6^A individual-nucleotide-resolution cross-linking and immunoprecipitation (miCLIP) technique, identification of m^6^A residues is not influenced by the peak shapes ([@b31-ijmm-43-06-2267]). Furthermore, identification of m^6^A residues by miCLIP is not restricted to a specified subset of DRACH (D=A, G) motifs ([@b2-ijmm-43-06-2267],[@b3-ijmm-43-06-2267],[@b13-ijmm-43-06-2267]). Therefore, miCLIP can properly identify m^6^A residues ([@b31-ijmm-43-06-2267]).

High-performance liquid chromatography (HPLC) or mass spectrometry are applied in some of the abovementioned methods to detect specific modified RNA or RNA bases ([@b3-ijmm-43-06-2267],[@b29-ijmm-43-06-2267]). Isolated RNA is fragmented into nucleosides prior to analysis, which may change the original RNA structure. Dot blot technology, which does not require fragmentation, is used as an alternative method to detect specific modifications. However, dot blot technology is limited in that RNA samples cannot be separated by the size, and hence, it is impossible to distinguish the targeted specific RNA in the RNA samples ([@b32-ijmm-43-06-2267],[@b33-ijmm-43-06-2267]). Notably, HPLC can be used alone to measure m^6^A modification rate ([@b18-ijmm-43-06-2267]).

The abovementioned methods and specific references are provided in [Table I](#tI-ijmm-43-06-2267){ref-type="table"} ([@b18-ijmm-43-06-2267],[@b26-ijmm-43-06-2267],[@b27-ijmm-43-06-2267],[@b29-ijmm-43-06-2267]-[@b51-ijmm-43-06-2267]). In the present review, the most recent information on the currently established m^6^A detection methods is presented and discussed.

2. Functions of m^6^A modifications
===================================

m^6^A is the most common type of RNA residue modification in eukaryotes ([@b2-ijmm-43-06-2267]-[@b4-ijmm-43-06-2267]). However, its specific biological roles remain largely unknown. Studies have indicated that the dynamic regulation of m^6^A has a significant impact on the control of gene expression ([@b20-ijmm-43-06-2267],[@b21-ijmm-43-06-2267]). m^6^A-seq has revealed that m^6^A predominantly exists on exons and the 3′-UTR of mRNA ([@b2-ijmm-43-06-2267]). METTL3, FTO and ALKBH5 have been identified to serve significant roles in biological regulation, including development, metabolism and fertility ([@b18-ijmm-43-06-2267],[@b19-ijmm-43-06-2267]).

FTO, an m^6^A demethylase, is recognized as a major obesity factor. It belongs to the ALKB enzyme family, which oxidatively demethylates m^6^A on mRNA ([@b32-ijmm-43-06-2267],[@b52-ijmm-43-06-2267]). ALKBH5 is another mammalian m^6^A demethylase, and is associated with certain mRNA-processing factors in nuclear speckles, which may influence RNA export and metabolism ([@b19-ijmm-43-06-2267]). ALKBH5-deficient mice have differential expression of genes involved in the p53 signaling pathway and spermatogenesis ([@b19-ijmm-43-06-2267]), suggesting a global role for m^6^A in human health. METTL3 is expressed in all human tissues and is highly expressed in the testis ([@b10-ijmm-43-06-2267],[@b11-ijmm-43-06-2267]). It has been identified that METTL3 can participate in tumor growth and progression by regulating the cell cycle of cancer cells ([@b53-ijmm-43-06-2267],[@b54-ijmm-43-06-2267]). WTAP was primarily recognized as a protein associated with Wilm\'s tumor and has been indicated to exhibit a significant role in cell cycle progression ([@b12-ijmm-43-06-2267]). WTAP also participates in RNA splicing and results in embryonic defects ([@b12-ijmm-43-06-2267]). Cooperation between the RNA m^6^A methyltransferase complex and the demethylases establishes a reversible regulation of RNA m^6^A modifications. Taken together, RNA m^6^A modifications exhibit significant roles in the molecular mechanisms of gene biology, as illustrated in [Fig. 1](#f1-ijmm-43-06-2267){ref-type="fig"}.

3. Methods used to analyze m^6^A modifications
==============================================

Dot blot
--------

Dot blot (or slot blot) technology is used in molecular biology as a semiquantitative or quantitative detection method for DNA, RNA and protein samples, and is predominantly used semiquantitatively in m^6^A analysis ([@b32-ijmm-43-06-2267],[@b33-ijmm-43-06-2267],[@b55-ijmm-43-06-2267]-[@b57-ijmm-43-06-2267]). Compared with western blotting, northern blotting or Southern blotting methods, dot blot technology has a simpler operation with a similar working principle. The biomolecules are not subjected to electrophoretic separation prior to detection with the dot blot method. Instead, samples containing a mixture of RNAs are directly applied to a membrane through an apparatus with circular templates that form a dot when the sample is applied. After applying a vacuum to embed RNAs and dry the membrane, biomolecules are detected with antibodies. When detecting RNA, the DNA must be removed prior to loading to eliminate its influence on m^6^A ([@b32-ijmm-43-06-2267],[@b33-ijmm-43-06-2267]). A schematic diagram of the determination of m^6^A modification residues by dot blot is presented in [Fig. 2](#f2-ijmm-43-06-2267){ref-type="fig"}.

Dot blot technology markedly saves time, since it does not require chromatography, gel electrophoresis or complex gel blocking procedures ([@b32-ijmm-43-06-2267],[@b33-ijmm-43-06-2267]). However, regarding m^6^A detection, dot blot technology is only able to verify the presence of m^6^A or compare the amounts of m^6^A between different groups ([@b32-ijmm-43-06-2267],[@b33-ijmm-43-06-2267]). Li *et al* ([@b32-ijmm-43-06-2267]) improved the traditional dot blot method to measure the global m^6^A abundance in the transcriptomes of four acute myeloid leukemia cell lines. However, this method is still not able to quantitate or precisely determine the location of m^6^A.

Methyl-sensitive MazF RNA endonucleases
---------------------------------------

The regulatory enzymes of m^6^A have been reported to contribute to tumorigenesis ([@b58-ijmm-43-06-2267]-[@b60-ijmm-43-06-2267]). While the significance of m^6^A has been confirmed, no convenient approach has been developed to analyze m^6^A methyltransferase and demethylase activities or to monitor the inhibitors of these activities.

The *Escherichia coli* toxin MazF exhibits endoribonuclease activity specific against ACA sequences and is susceptible to m^6^A. MazF is the first enzyme discovered with the ability to specifically cleave RNA containing m^6^A, and is used to study activities of m^6^A demethylase and methyltransferase ([@b34-ijmm-43-06-2267]). Furthermore, MazF has an application for monitoring the inhibitors of m^6^A methyltransferase and demethylase. RNA cleavage by MazF may be detected by polyacrylamide gel electrophoresis and the fluorescence-resonance energy transfer-based plate assay ([@b61-ijmm-43-06-2267]). A schematic diagram of the determination of m^6^A modification residues by methyl-sensitive MazF RNA endonucleases is presented in [Fig. 3](#f3-ijmm-43-06-2267){ref-type="fig"}.

At the current stage of development, the MazF cleavage methods are restricted regarding the evaluation of m^6^A, as MazF is only able to cleave the 5′-ACA-3′ site in single-stranded RNA, frequently occurring in endogenous RNAs. However, MazF is not able to cleave the 5′-ACA-3′ site in double-stranded RNA ([@b61-ijmm-43-06-2267]), and thus, it may not accurately determine the presence of m^6^A in structured RNA.

Immuno-northern blot
--------------------

The immuno-northern blot combines a northern blotting experimental program and m^6^A-binding antibody, which is different from conventional northern blot techniques that use DNA probes. Immuno-northern blot does not require RNA fragmentation prior to analysis and the RNAs are separated based on their molecular weights ([@b35-ijmm-43-06-2267]). Thus, the detection of m^6^A modifications by immuno-northern blot is applied in various types of RNA ([@b35-ijmm-43-06-2267]).

In brief, RNAs are separated in a denaturing acryl-amide gel or an agarose gel and then transferred onto nylon membranes. The RNA strands on the membranes are exposed to ultraviolet (UV) irradiation for cross-linking, followed with incubation with primary antibodies against m^6^A modifications, corresponding secondary antibody and chemiluminescent detection ([@b35-ijmm-43-06-2267]).

4. Quantification of m^6^A modifications
========================================

RNA photo-crosslinkers and quantitative proteomics
--------------------------------------------------

The regulatory role of mRNA predominantly depends on the interaction between mRNA and RNA-binding proteins to regulate RNA splicing, stability, localization and translation ([@b62-ijmm-43-06-2267]). Photo-crosslinking technologies are diffusely applied to stabilize direct protein-RNA interactions ([@b63-ijmm-43-06-2267]). These technologies depend on the tendency for UV-induced photochemistry of nucleobases, which are natural or derivatives containing sulfur or halogen substituents. Photo-affinity labels, including diazirine ([@b64-ijmm-43-06-2267]) or benzophenone ([@b65-ijmm-43-06-2267]), are not widely used in the analysis of protein-RNA interactions; however, they may be activated by longer wavelengths and provide more efficient crosslinking.

Arguello *et al* ([@b29-ijmm-43-06-2267]) developed a chemical proteomics approach based on photo-crosslinking of the RNA base and diazirine, which was highly efficient in quantitatively analyzing protein-RNA interactions regulated by m^6^A modification. By using this method, novel m^6^A \'readers\' have been discovered. To isolate m^6^A readers with photosynthetic and quantitative proteomics, RNA probes are required to contain the following: i) m^6^A molecules; ii) a photo-crosslinker that is efficient and does not influence the protein-RNA interactions; iii) streptavidin as an affinity handle for protein enrichment. A probe was prepared that contains the sequence GGm^6^ACU, the common recognition pattern of the m^6^A site in mammalian cells. This sequence is indispensable for binding the YTH-domain proteins ([@b66-ijmm-43-06-2267],[@b67-ijmm-43-06-2267]). The probe was validated by known m^6^A RNA \'readers\', including YTHDF1 ([@b20-ijmm-43-06-2267]), YTHDF2 ([@b21-ijmm-43-06-2267]), YTHDF3 ([@b3-ijmm-43-06-2267],[@b22-ijmm-43-06-2267],[@b68-ijmm-43-06-2267]) and YTHDC1 ([@b22-ijmm-43-06-2267]). A schematic diagram of the detection of m^6^A modification residues by the RNA photo-crosslinkers and quantitative proteomics technologies is presented in [Fig. 4](#f4-ijmm-43-06-2267){ref-type="fig"}. We hypothesize that the requirement of the synthesis of the sensor may be a limitation regarding these techniques.

Electrochemical immunosensor method
-----------------------------------

The majority of the abovementioned analytic methods are difficult to perform and expensive. The electrochemical immunosensor method was developed to provide convenience and high sensitivity ([@b30-ijmm-43-06-2267]). An anti-m^6^A antibody has been used to detect m^6^A by targeting m^6^A-5′-triphosphate (m^6^ATP). The detection and capture of m^6^A relies on silver nanoparticles and SiO~2~ (Ag\@SiO~2~) nano-spheres with amine-polyethylene glycol 3-biotin. Ag\@SiO~2~ nanospheres were prepared to amplify signals. Phos-tag-biotin was prepared to link m^6^ATP and Ag\@SiO~2~ through two types of specific interaction between phosphate group of m^6^ATP and phos-tag, biotin and streptavidin, respectively. Experiments for evaluating this strategy indicated that the immuno-sensor has acceptable reproducibility and specificity with a wide linear range and a low detection limit. A schematic diagram for the determination of m^6^A modification residues by the electrochemical immunosensor method is presented in [Fig. 5](#f5-ijmm-43-06-2267){ref-type="fig"}.

The efficacy of the detection of the m^6^A content using the electrochemical immunosensor method had been verified in human cell lines ([@b30-ijmm-43-06-2267]). It also provides a technological basis for the detection of RNAs and DNAs with the advantages of convenience, low cost, and high specificity and sensitivity.

Vector method to detect m^6^A sites
-----------------------------------

High-throughput next-generation sequencing-based technology for identifying m^6^A sites based on where adenosine is methylated has not been applied in most species. In recent years, a vector machine method was developed to identify m^6^A sites in *Arabidopsis thaliana* ([@b37-ijmm-43-06-2267]). When combining anti-m^6^A antibodies and high-throughput sequencing, Luo *et al* ([@b69-ijmm-43-06-2267]) obtained thousands of m^6^A peaks for *A. thaliana*, including \'common\' m^6^A peaks. Since the RRACH motif, where R resembles purine, A stands for m^6^A and H resembles a non-guanine base ([@b69-ijmm-43-06-2267]), was identified in most of the m^6^A peaks, Chen *et al* ([@b37-ijmm-43-06-2267]) collected segments containing RRACH at the center of the \'common\' m^6^A peaks and proposed a model that may accurately identify specific m^6^A sites with high accuracy.

If the model is adapted to other plant species other than *A. thaliana*, this vector machine-based method may be used for the detection of m^6^A and other post-transcriptional modifications in these other plants as well.

5. Methods to determine m^6^A residue locations
===============================================

HRM
---

HRM analysis is a simple method to detect m^6^A modification residues at a specific location in RNAs ([@b38-ijmm-43-06-2267]). HRM may be applied to high-throughput measurement. The resulting HRM curves of the samples of RNA mixtures change steadily from 100% of methylated RNA to 100% of unmethylated RNA ([@b38-ijmm-43-06-2267]). As presented in [Fig. 6](#f6-ijmm-43-06-2267){ref-type="fig"}, the detection of m^6^A modification residues by the HRM method relies on the modified nucleoside position at a particular site of RNA and is followed by rapid screening for conditions or genes necessary for analysis of that modification ([@b38-ijmm-43-06-2267]).

According to the specificity of the oligonucleotide probe hybridization, bulk cellular RNA, as opposed to purified specific RNA, has been designed for detecting m^6^A at a pre-defined position ([@b38-ijmm-43-06-2267]). In addition, partial non-ribosomal target enrichments may be easily accomplished using commercially available kits.

A possible application for this method would be to screen knockout/knockdown strain libraries to identify genes contributing to the formation of a specific m^6^A nucleoside. Another possible application is to detect the presence of a particular m^6^A nucleoside under different growth or environmental conditions ([@b2-ijmm-43-06-2267],[@b3-ijmm-43-06-2267]). HRM analysis may help to elucidate the dynamic events that result in the modification of certain RNAs.

m^6^A level and isoform-characterization sequencing (m^6^A-LAIC-seq)
--------------------------------------------------------------------

For thorough investigation of the m^6^A epitranscriptome, Molinie *et al* ([@b27-ijmm-43-06-2267]) invented the m^6^A-LAIC-seq technique. Combined with RNA IP whole-transcriptome sequencing, m^6^A-LAIC-seq may quantify m^6^A contents, with spike-in RNAs as an internal standard. A schematic diagram for the determination of m^6^A modification residues by m^6^A-LAIC-seq is presented in [Fig. 7](#f7-ijmm-43-06-2267){ref-type="fig"}. The results demonstrate a quantitative road map to which genes are the most or the least likely to be influenced by m^6^A-dependent regulatory networks. This method may determine the m^6^A levels in each gene but cannot stoichiometrically analyze the methylation of a single modified nucleotide. m^6^A-LAIC-seq complements m^6^A-seq identification of methylation sites and helps to expand the understanding of the biology of m^6^A.

Site-specific cleavage and radioactive labeling followed by ligation-assisted extraction and thin-layer chromatography (SCARLET)
--------------------------------------------------------------------------------------------------------------------------------

To elucidate the dynamic biological functions of m^6^A, Liu *et al* ([@b40-ijmm-43-06-2267]) provided the SCARLET method that directly measures the precise location and the status of m^6^A modification at any candidate site of mRNA/lncRNA at a single nucleotide resolution. In addition to m^6^A, SCARLET may be used to observe other RNA modifications, including 5-methylcytosine, pseudouridine and 2′-O-methyl ribonucleosides. SCARLET is available to study the biological functions of RNA modifications with general experimental equipment and materials. A schematic diagram for the determination of m^6^A modification residues by SCARLET is presented in [Fig. 8](#f8-ijmm-43-06-2267){ref-type="fig"}.

The feasibility of using the SCARLET method has been confirmed in HeLa cell RNA samples, which produced similar results compared with previously reported m^6^A sites in Hela samples. Using this method, a minimally modified m^6^A site that was not precisely determined in a preceding study was also identified, demonstrating that SCARLET is able to easily resolve the ambiguity of modification sites ([@b70-ijmm-43-06-2267]).

MeRIP-Seq
---------

Although RNA methylation has been identified and verified in the 1970s, the relevant modification mechanism, regulatory means and biological significance have not been clarified due to technical limitations. The recent emergence of MeRIP-Seq technology makes it possible to study m^6^A methylation at the transcriptome level by high-throughput sequencing ([@b2-ijmm-43-06-2267],[@b3-ijmm-43-06-2267]).

MeRIP-Seq is a combination of ChIP-Seq and RNA-Seq that is able to elucidate global mRNA m^6^A sites in mammalian cells. MeRIP-seq is a novel type of IP-seq technology, in which the known ChIP-seq, photoactivatable ribonucleo-side-enhanced crosslinking and IP (a more mature sequence), is applied. MeRIP-seq has been successfully used to detect whole-genome m^6^A modifications ([@b42-ijmm-43-06-2267]-[@b46-ijmm-43-06-2267]). The major principle of this technique is as follows: The anti-m^6^A antibody is incubated with randomly interrupted RNA fragments using a co-IP method resulting in an m^6^A modification fragment that is precipitated and sequenced. Concurrently, a control sample is run that eliminates the background during antibody capture ([@b2-ijmm-43-06-2267]).

Successful preparations of each library should be evaluated prior to massive parallel sequencing. To identify and localize the m^6^A sites at a transcriptome-wide level by m^6^A IP, fragmentation of poly(A)^+^-selected RNAs (input) is required prior to IP with anti-m^6^A antibodies. The input and m^6^A IP RNAs are then separately processed for next-generation sequencing ([@b2-ijmm-43-06-2267]). Zhang *et al* ([@b48-ijmm-43-06-2267]) first proposed a Bayesian statistical model, BaySeqPeak, to analyze MeRIP-Seq data to help discover methylation site signals in the transcriptome. A reference transcriptome was prepared, which contains a single, non-intron splice variant of each gene. The resultant reads were then specifically compared with the reference to identify m^6^A sites with a low false-detection rate ([@b3-ijmm-43-06-2267]). A schematic diagram for the determination of m^6^A modification residues by MeRIP-Seq is presented in [Fig. 9](#f9-ijmm-43-06-2267){ref-type="fig"}.

MiClip
------

It has been reported that m^6^A residues may be located by producing unique signature mutations with anti-m^6^A antibodies and UV crosslinking techniques ([@b31-ijmm-43-06-2267]). m^6^A residues were mapped with two antibodies, one of which translates C to T to detect single and clustered m^6^A residues, and the other antibody that produces truncations is used to determine the position of m^6^A sites and detect m^6^A residues concurrently. A schematic diagram for the determination of m^6^A modification residues by miClip is provided in [Fig. 10](#f10-ijmm-43-06-2267){ref-type="fig"}.

Identification of m^6^A residues by direct detection is superior to that by bioinformatics predictions from MeRIP-Seq peaks ([@b31-ijmm-43-06-2267]). The reliability of bioinformatics prediction depends on the characteristics of the m^6^A peak. MeRIP-Seq can accurately predict m^6^A residues only with a single clear peak of a single m^6^A residue and is limited to the centrally-located DRACH motif ([@b31-ijmm-43-06-2267]). m^6^A residues usually cluster in mRNAs, resulting in multiple MeRIP-Seq peaks ([@b2-ijmm-43-06-2267]). Identification of m^6^A residues using miCLIP technology is not influenced by peak shapes and not confined to the centrally-located DRACH motif. Therefore, miCLIP can correctly identify m^6^A residues.

A DNA polymerase for direct m^6^A sequencing
--------------------------------------------

At present, RNA samples are prepared by antibody-based enrichment of m^6^A residues prior to sequencing, as m^6^A modifications are usually lost after reverse transcription ([@b25-ijmm-43-06-2267],[@b26-ijmm-43-06-2267]). The indirect detection may lead to a higher error rate, pushing the generation of novel DNA polymerase to sequence m^6^A directly ([@b26-ijmm-43-06-2267]). In this light, Aschenbrenner *et al* ([@b26-ijmm-43-06-2267]) developed a screening method to develop a reverse transcription-active KlenTaq DNA polymerase variant for labeling N^6^-methylation residues. A schematic diagram for the determination of m^6^A modification residues by the DNA polymerase for direct N^6^-methyladenosine sequencing is presented in [Fig. 11](#f11-ijmm-43-06-2267){ref-type="fig"}.

HPLC
----

The development of HPLC occurred only 30 years ago; however, the development of this separation analysis technology is very rapid, and is now widely used, including in the detection of m^6^A modification ([@b50-ijmm-43-06-2267]). HPLC was firstly used to detect m^6^A modification in nine DNAs ([@b50-ijmm-43-06-2267]). Subsequently, Rana and Tuck ([@b49-ijmm-43-06-2267]) applied HPLC in the detection of m^6^A modification in a T7 RNA transcript coding for mouse dihydrofolate reductase by separating m^6^A from adenine, cytosine, uracil and so on. In a study by Jia *et al* ([@b18-ijmm-43-06-2267]), HPLC helped observe the changes of the m^6^A ratio in mRNAs following FTO treatment to better understand the function of FTO. The development of this *in vitro* methylation assay opened the door for studies investigating m^6^A levels in specific mRNAs or learn the biological significance of m^6^A modification.

6. Discussion
=============

Detection of RNA modifications and study of their functions are emerging fields of research. The potential role of m^6^A modifications in regulating molecular and physiological processes in several organisms, particularly in RNA stability, splicing, transport, localization and translation, is valued ([@b19-ijmm-43-06-2267],[@b20-ijmm-43-06-2267],[@b52-ijmm-43-06-2267],[@b21-ijmm-43-06-2267],[@b70-ijmm-43-06-2267]-[@b73-ijmm-43-06-2267]). With the discovery of \'reader\' proteins, the downstream molecular mechanisms of m^6^A modifications are gradually being clarified ([@b21-ijmm-43-06-2267]). There is strong evidence that m^6^A methylation is associated with RNA splicing and that \'readers\' of m^6^A reduce the stability of RNA transcripts ([@b21-ijmm-43-06-2267]). After removal of m^6^A, a second class of proteins may bind to the RNAs, which may be affected by changes of the RNA secondary structure from m^6^A additions ([@b74-ijmm-43-06-2267]). Thus, the physiological effects of m^6^A modifications should be observed at multiple levels, including the tissue level, the pathway level, the cellular level and the molecular level ([@b75-ijmm-43-06-2267]). An increasing number of studies have suggested a link between m^6^A RNA modifications with cancer and other similar disease-associated processes ([@b32-ijmm-43-06-2267],[@b53-ijmm-43-06-2267],[@b54-ijmm-43-06-2267],[@b73-ijmm-43-06-2267],[@b74-ijmm-43-06-2267]-[@b76-ijmm-43-06-2267]). Detection of m^6^A modification *in vitro* can help identify the precise regulatory forms and synergistic roles of m^6^A modifications in cancer and other diseases ([@b32-ijmm-43-06-2267],[@b53-ijmm-43-06-2267],[@b54-ijmm-43-06-2267],[@b74-ijmm-43-06-2267]-[@b76-ijmm-43-06-2267]). Certain m^6^A methylases, m^6^A demethylases or downstream genes have become prognostic factors for different cancer types ([@b77-ijmm-43-06-2267]-[@b79-ijmm-43-06-2267]). Certain abovementioned methods, including MeRIP-seq, could help identify the downstream genes and mutation sites ([@b54-ijmm-43-06-2267],[@b80-ijmm-43-06-2267]). Therefore, detection of them *in vitro* may help diagnose and predict the final progress. The present review provides an overview of these methods to drive the elucidation of the biological roles of m^6^A and encourage their further development.
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![Roles of the N^6^-methyladenosine Writer, Eraser and Reader complexes in regulating mRNA. RNA m^6^A modifications serve important roles in the molecular mechanisms of gene biology. METTL, methyltransferase like; WTAP, WT1-associated protein; VIRMA, Vir like m^6^A methyltransferase associated; RBM15, RNA binding motif protein 15; YTHD, YT521-B homology; IGF2BP1/2/3, insulin link growth factor 2 mRNA binding protein 1/2/3; elF3, E74-like factor 3.](IJMM-43-06-2267-g00){#f1-ijmm-43-06-2267}

![Schematic diagram of dot blot technology. Samples containing a mixture of RNAs are directly applied to a NC membrane. The membrane is then dried and detected with antibodies. The filled circle represents a detected signal. NC, nitrocellulose filter.](IJMM-43-06-2267-g01){#f2-ijmm-43-06-2267}

![Schematic diagram of fluorescence resonance electron transfer-based MazF assays. RNAs are cleaved by MazF at the 5′-ACA-3′ site in single-stranded RNAs and detected by fluorescence assay. m^6^A, N^6^-methyladenosine; A, adenine; C, cytosine; BHQ1, black hole quencher-1.](IJMM-43-06-2267-g02){#f3-ijmm-43-06-2267}

![Schematic diagram of RNA photo-crosslinkers and quantitative proteomics. RNA probes are required to contain the following: i) m^6^A molecules; ii) a photo-crosslinker that is efficient and does not influence the protein-RNA interactions; and iii) streptavidin as an affinity handle for protein enrichment. m^6^A, N^6^-methyladenosine; LC-MS/MS, liquid chromatography-mass spectrometry/mass spectrometry; hv, irradiation with light.](IJMM-43-06-2267-g03){#f4-ijmm-43-06-2267}

![Schematic diagram of the electrochemical immunosensor method. Ag\@SiO~2~ nanospheres are prepared to amplify signals. Phos-tag-biotin is prepared to link m^6^ATP and Ag\@SiO~2~ through two types of specific interaction between the phosphate group of m^6^ ATP and phos-tag, biotin and streptavidin. m^6^A, N^6^-methyladenosine; Ag\@SiO~2~, silver nanoparticles and SiO~2~; GCE, glassy carbon electrode; MPBA, P-mercaptobenzenboric acid; EDC, 1-ethyl-3-(3′-dimeth-ylaminopropyl) carbodiimide; NHS, N-hydroxysuccinimide.](IJMM-43-06-2267-g04){#f5-ijmm-43-06-2267}

![Schematic diagram of high-resolution melting analysis. The green and orange curves corresponded to the different types of strains (wild-type or gene mutation, respectively). qPCR, quantitative polymerase chain reaction; cDNA, complementary DNA; Tm, melting temperature.](IJMM-43-06-2267-g05){#f6-ijmm-43-06-2267}

![Schematic diagram of m^6^A-level and isoform-characterization sequencing. Poly A RNAs bind with anti-m^6^A antibody. A vast excess of antibody, as a second round of anti-m^6^A RIP on the m^6^A-negative fraction recovers no further RNA. m^6^A levels per gene are quantified by the ratio of RNA abundance as follows: Eluate/(eluate + supernatant). m^6^A, N^6^-methyladenosine; poly A, polyadenylated; IP, immunoprecipitation; RIP, radioimmunoprecipitation; NGS, next-generation sequencing; ERCC, External RNA Controls Consortium; pos, positive; neg, negative.](IJMM-43-06-2267-g06){#f7-ijmm-43-06-2267}

![Schematic diagram of the site-specific cleavage and radioactive labeling followed by ligation-assisted extraction and thin-layer chromatography technique. m^6^A, N^6^-methyladenosine; TLC, thin layer chromatography; polyA, polyadenylated; pm^6^A, 32P-labeled N^6^-methyladenosine.](IJMM-43-06-2267-g07){#f8-ijmm-43-06-2267}

![Schematic diagram of m^6^A/methylated RNA immunopre-cipitation sequencing. Fragmentation of poly(A)^+^-selected RNAs (input) is required prior to IP with anti-m^6^A antibodies. The input and m^6^A IP RNAs are then separately processed for next-generation sequencing. m^6^A, N^6^-methyladenosine; UTR, untranslated region; IP, immunoprecipitation.](IJMM-43-06-2267-g08){#f9-ijmm-43-06-2267}

![Schematic diagram of miCLIP technology. m^6^A residues can be mapped by generating unique signature mutations with m^6^A-specific antibodies and UV crosslinking, followed by analysis by sequencing. miCLIP, N^6^-methyladenosine individual-nucleotide-resolution cross-linking and immunoprecipitation; UV, ultraviolet; m^6^A, N^6^-methyladenosine; iCLIP, individual nucleotide resolution CLIP.](IJMM-43-06-2267-g09){#f10-ijmm-43-06-2267}

![Schematic diagram of a DNA polymerase for direct m^6^A sequencing. This is based on the reverse transcriptase variants exhibiting RT-signatures as a response to encountering a specific RNA modification. m^6^A, N^6^-methyladenosine; nt pos, nucleotide position; RT, reverse transcription.](IJMM-43-06-2267-g10){#f11-ijmm-43-06-2267}

###### 

Methods for detecting m^6^A residues.

  Method                                                (Refs.)
  ----------------------------------------------------- ------------------------------------------------------------------------
  Semi-quantitative                                     
   Dot blot technology                                  ([@b32-ijmm-43-06-2267],[@b33-ijmm-43-06-2267])
   Methyl sensitivity of MazF RNA endonucleases         ([@b34-ijmm-43-06-2267])
   Immune-northern blot                                 ([@b35-ijmm-43-06-2267],[@b36-ijmm-43-06-2267])
  Quantitative                                          
   RNA photo-crosslinkers and quantitative proteomics   ([@b29-ijmm-43-06-2267])
   Electrochemical immunosensor method                  ([@b30-ijmm-43-06-2267])
   Support vector machine-based method                  ([@b37-ijmm-43-06-2267])
  Detection of precise locations                        
   HRM                                                  ([@b38-ijmm-43-06-2267])
   LAIC                                                 ([@b27-ijmm-43-06-2267],[@b39-ijmm-43-06-2267])
   SCARLET                                              ([@b39-ijmm-43-06-2267]-[@b41-ijmm-43-06-2267])
   MeRIP-seq                                            ([@b42-ijmm-43-06-2267]-[@b46-ijmm-43-06-2267])
   MiClip                                               ([@b31-ijmm-43-06-2267],[@b39-ijmm-43-06-2267],[@b47-ijmm-43-06-2267])
   DNA polymerase for direct m^6^A sequencing           ([@b26-ijmm-43-06-2267],[@b48-ijmm-43-06-2267])
   HPLC                                                 ([@b18-ijmm-43-06-2267],[@b49-ijmm-43-06-2267]-[@b51-ijmm-43-06-2267])

m^6^A, N^6^-methyladenosine; miCLIP, m^6^A individual-nucleotide-resolution cross-linking and immunoprecipitation; HRM, high-resolution melting analysis; SCARLET, site-specific cleavage and radioactive labeling followed by ligation-assisted extraction and thin layer chromatography; LAIC, level and isoform characterization; MeRIP-seq, methylated RNA immunoprecipitation sequencing; MiClip, m^6^A individual-nucleotide-resolution cross-linking and immunoprecipitation; HPLC, high-performance liquid chromatography.
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